ResApp (ASX:RAP) share price rockets 11% on new Johnson & Johnson deal

It's been a good day for the digital health company's shares…

| More on:
Jumbo Interactive staffers shaking hands around table agreeing to an acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is soaring during early afternoon trade on Thursday. This comes after the digital health company announced a licensing agreement with global pharmaceutical company, Johnson & Johnson.

At the time of writing, ResApp shares are up 11.32% to 5.9 cents a pop, having earlier jumped to 6.5 cents.

ResApp licenses ResAppDx technology

Investors are driving up the ResApp share price following the company's latest update.

According to its release, ResApp has secured a three-year, non-exclusive licensing agreement with Janssen Pharmaceutica NV. The latter is one of the Janssen pharmaceutical companies of Johnson & Johnson.

The deal will see ResApp provide its ResAppDx technology to Janssen in a respiratory syncytial virus (RSV) clinical trial.

ResAppDx is a smartphone-based acute respiratory diagnostic test that has been developed to diagnose a range of health issues. 

The technology will be used to assess respiratory symptoms of a group of patients with a range of respiratory diseases.

Typically mild and similar to the common cold, RSV symptoms in severe cases can spread to the lower respiratory tract. This causes pneumonia or acute exacerbations of chronic obstructive pulmonary disease (COPD) or asthma.

The trial will run across a number of continents including the United States, Europe, South America, and Asia-Pacific.

Janssen will pay for the development and maintenance costs as well as a fee for each ResAppDx test. The clinical trial is expected to commence later this calendar year.

Commenting on the announcement driving the ResApp share price, CEO and managing director Dr Tony Keating said:

Almost 160,000 people die each year worldwide as a consequence of RSV. ResApp Health is proud to be supporting Janssen in further understanding the impact of this disease on individual patients, which may help to inform prevention and treatment strategies.

With this agreement, we are demonstrating that leading global pharmaceutical companies see the value of ResAppDx in a clinical trial setting. While not expected to have a material impact on our operating results at this stage, this contract represents the beginning of our commercial relationship with Janssen and will further build the body of high quality, clinical evidence regarding the use of ResAppDx.

ResApp share price snapshot

Despite today's positive announcement, ResApp shares have failed to take off in 2021, down around 30%. When looking over the past 12 months, the company's shares have fallen more than 34%.

ResApp presides a market capitalisation of roughly $45.5 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two lab workers fist pump each other.
Broker Notes

What's JP Morgan's price target on CSL shares?

Are CSL shares undervalued or will they continue to underperform?

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

2 ASX healthcare stocks making huge moves on big news

These shares are getting investors excited today. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is up 15% on guidance upgrade?

Let's find out what is getting investors excited on Tuesday.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

3 reasons why the Sigma Healthcare share price could be a buy

This business has a very exciting outlook.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »